Fundraising Fox
Obsidiantx
Founded 2015 · 108 employees on LinkedIn · 4 known investors
Find your way into Obsidiantx
Sign up to see every warm intro you have to Obsidiantx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Obsidiantx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.
Founders & leadership
Obsidiantx was founded in 2015 by Peter Barrett and Tom Wandless.
PB
TW
Tom WandlessScientific Founder
MJ
Madan JagasiaChief Executive OfficerMadan Jagasia is CEO of Obsidian Therapeutics, which develops engineered cell therapies for solid tumors. He holds a medical background with expertise in oncology and clinical research, and earned a master's degree in clinical investigation from Vanderbilt University and an MBA in healthcare management from Owen Graduate School of Management.
JP
Jennifer PetersonChief People OfficerJennifer Peterson serves as Chief People Officer at Obsidian Therapeutics, where she develops organizational and talent strategies. With approximately 15 years in executive roles across public and private companies in software and biotech sectors, she has led teams through growth, transformation, and organizational building.
Investors · 4
Atlas Venturelisted by Atlas VentureCambridge · $500K – $1M
How we know: Atlas Venture's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Obsidiantx do?
- Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.
- Who founded Obsidiantx?
- Obsidiantx was founded by Peter Barrett, Tom Wandless in 2015.
- Who are Obsidiantx's investors?
- Obsidiantx's investors include Atlas Venture, TCG Crossover, Vertex Ventures HC, Wellington Management.